To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: European Commission Approves Icatibant for the Treatment of Hereditary Angio-Oedema URL: http://www.pslgroup.com/dg/225CBA.htm Doctor's Guide July 15, 2008
CAMBRIDGE, Mass -- July 15, 2008 -- The European Commission has approved icatibant (Firazyr) in the treatment of acute attacks of hereditary angio-oedema (HAE). Among the key benefits of icatibant for patients, are its safety and efficacy profile demonstrated in clinical studies to date, subcutaneous administration, and room temperature stability. SOURCE: Shire --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.